Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.51 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 6/20 | 0.48 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | REN | P00797 | 2/20 | 0.44 |
| ▸ | LGMN | Q99538 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10270249 | 0.90 | CTSK (0.50) | CTSKCTSSCTSLATMKMT2A | |
| SCHEMBL9103298 | 0.90 | CTSK (0.52) | CTSKCTSSCTSLATMKMT2A | |
| SCHEMBL9103286 | 0.90 | CTSK (0.52) | CTSKCTSSCTSLATMKMT2A | |
| SCHEMBL10270427 | 0.88 | CTSL (0.60) | CTSKCTSSCTSLATMKMT2A | |
| SCHEMBL10270251 | 0.86 | CTSK (0.48) | CTSKCTSSCTSLATMKMT2A | |
| SCHEMBL10270703 | 0.83 | GAA (0.46) | CTSKCTSSCTSLATMKMT2A | |
| SCHEMBL10270885 | 0.82 | CTSL (0.45) | CTSKCTSSCTSLATMKMT2A | |
| SCHEMBL9104768 | 0.82 | ALDH1A1 (0.52) | CTSKCTSSCTSLALDH1A1SMN1; SMN2 | |
| SCHEMBL9104776 | 0.82 | ALDH1A1 (0.52) | CTSKCTSSCTSLALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9107133 | 0.81 | ALDH1A1 (0.51) | CTSKCTSSCTSLALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142668-A1 | CATHEPSIN C INHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142668-A1 | CATHEPSIN C INHIBITORS | CTSE, CTSB, CTSS | CTSK 8/4885CTSS 3/4885CTSL 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.